1
Orphan Designations
0 approved
0
FDA Approvals
0
Active Trials
3
Rare Diseases
across 4 areas
0
News (30d)
Quiet
MiNA Alpha, Ltd is a company with 1 orphan drug designation across 3 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| adult hepatocellular carcinoma | a liposomal formulation of CEBPA-51, an saRNA duplex in sucrose/phosphate buffer | Des.TrialAppr. |
| hepatocellular carcinoma | a liposomal formulation of CEBPA-51, an saRNA duplex in sucrose/phosphate buffer | Des.TrialAppr. |
| pediatric hepatocellular carcinoma | a liposomal formulation of CEBPA-51, an saRNA duplex in sucrose/phosphate buffer | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
18
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
18
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
0
affecting portfolio